Recently added
This page was added on 22 June 2026.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Sponsor
Merck Sharp & Dohme (Australia)
Administration route
Intramuscular injection
Vaccine group
Monovalent vaccines
Description:
Registered for use in people aged ≥18 years
21vPCV - 21-valent pneumococcal conjugate vaccine
Each 0.5 mL dose of vaccine contains:
- 2.0µg each of pneumococcal purified capsular polysaccharide serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, deOAc15B, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) conjugated to approximately 65 mcg of diphtheria CRM197 protein.
- Polysorbate 20
- Histidine
Antigens are conjugated to approximately 65 µg of diphtheria CRM197 protein.
For Product Information and Consumer Medicine Information about Capvaxive visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
Page history
Last updated
Last reviewed
Related diseases